HAVCR2 and neoplasm: In addition, ETO improves the therapeutic effect of TIM-3 (hepatitis A virus cellular receptor 2) monoclonal antibody in a tumor-bearing mouse model, further enhancing the CD8+ T cell-mediated anti-tumor immune response.